A statistician analyzes data from a randomized, double-blind, placebo-controlled study and finds that the placebo outperformed the investigational product. Which of the following is a plausible explanation for this?
Answer(s): C
In a randomized, double-blind, placebo-controlled study, if statistical analysis shows that the placebo appears to outperform the investigational product, a likely cause is a data management or coding error, particularly in treatment code entry or mapping. According to the GCDMP (Chapter: Database Design and Build), treatment assignment data -- typically stored in randomization or code-break files -- must be accurately integrated into the clinical database. Any mismatch between randomization codes, subject identifiers, or treatment arms can lead to incorrect grouping during analysis, producing false conclusions such as placebo superiority. The Data Manager should initiate a root cause review of randomization data integration and treatment mapping. The placebo is never designed to have active medicinal effects (option A). Option D is incorrect because the described scenario implies a data inconsistency, not true efficacy differences. Proper verification of randomization coding and reconciliation between data management and statistical programming systems are essential.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Build, Section 6.1 Randomization and Treatment Code Management ICH E6 (R2) GCP, Section 5.5.3 Data Verification and Coding Accuracy FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations Data Mapping and Validation Requirements
Which is the best way to identify sites with high subject attrition?
Answer(s): A
The best method to identify sites with high subject attrition is to calculate the proportion of patients for which two visit periods have passed without data, by site. According to the GCDMP (Chapter: Data Quality Assurance and Control), subject attrition is an important performance indicator for data completeness and site compliance. Evaluating missing or delayed data across multiple consecutive visit periods allows for early detection of potential dropouts or site-level operational issues.By assessing this proportion at the site level, the Data Manager can distinguish between random missing data and systematic site underperformance. Counting or proportioning late visits (options B and C) identifies scheduling delays, not attrition. Looking at missing data without site context (option D) fails to identify site-specific patterns, limiting corrective action. This metric aligns with risk-based monitoring (RBM) practices recommended by ICH E6 (R2) and FDA RBM Guidance, which promote proactive identification of sites at risk of data loss.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 5.4 Site Performance MetricsICH E6 (R2) Good Clinical Practice, Section 5.18 Monitoring and Site Performance Evaluation FDA Guidance for Industry: Oversight of Clinical Investigations Risk-Based Monitoring, Section 6 Site Performance Metrics
When a data manager runs a report on resolution types of discrepancy status, which of the following would NOT be a part of resolution types?
Answer(s): B
In a discrepancy management workflow, "Received from site and not yet reviewed" is not a resolution type -- it represents a status, not a final resolution outcome. According to the GCDMP (Chapter: Data Validation and Cleaning), resolution types describe how a data discrepancy was finalized or addressed, such as:Resolved with data correction,Confirmed as correct (no change required),Self-evident correction applied by data management, orUnresolvable discrepancies documented.In contrast, statuses describe the stage of the query (e.g., open, sent, answered, pending review, closed). "Received from site and not yet reviewed" indicates an intermediate workflow state where the response awaits validation by data management.Proper classification of resolution types is essential for performance reporting, audit readiness, and ensuring the traceability of query management actions under ICH E6 (R2) and FDA 21 CFR Part 11.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.3 Discrepancy Resolution LifecycleICH E6 (R2) Good Clinical Practice, Section 5.5.3 Data Handling and Record Management FDA 21 CFR Part 11 Electronic Records; Audit Trails and Discrepancy Tracking Requirements
Which type of edit check would be implemented to check the correctness of data present in a text box?
A front-end check is a type of real-time validation performed at the point of data entry--typically within an Electronic Data Capture (EDC) system or data entry interface--designed to ensure that the data entered in a text box (or any input field) is valid, logically correct, and within expected parameters before the user can proceed or save the record. According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), edit checks are essential components of data validation that ensure data accuracy, consistency, and completeness. Front-end checks are implemented within the data collection interface and are triggered immediately when data are entered. They prevent invalid entries (such as letters in numeric fields, out-of-range values, or improper date formats) from being accepted by the system.Examples of front-end checks include:Ensuring a numeric field accepts only numbers (e.g., weight cannot include text characters).Validating that a date is within an allowable range (e.g., not before the subject's date of birth). Requiring mandatory fields to be completed before moving forward. This differs from back-end checks or programmed checks, which are typically run later in batch processes to identify data inconsistencies after entry. Manual checks are human-performed reviews, often for context or data that cannot be validated automatically (e.g., narrative assessments). Front-end edit checks are preferred wherever possible because they prevent errors at the source, reducing the number of downstream data queries and cleaning cycles. They contribute significantly to data quality assurance, regulatory compliance, and efficiency in data management operations.
(CCDM-Verified Sources)Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.2 Edit Checks and Real-Time Data Validation FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 Data Entry and Verification ControlsICH E6 (R2) Good Clinical Practice, Section 5.5 Data Handling and Record Integrity CDISC Operational Data Model (ODM) Specification Edit Check Implementation Standards
Who has primary responsibility for ensuring accurate completion of the CRF?
Answer(s): D
The Investigator holds the primary responsibility for ensuring the accuracy, completeness, and timeliness of Case Report Form (CRF) entries. This responsibility is mandated by regulatory requirements under ICH E6(R2) Good Clinical Practice (GCP). The investigator may delegate CRF completion to a qualified designee (e.g., site coordinator), but the ultimate accountability remains with the investigator. The investigator's signature (electronic or manual) on the CRF serves as certification that the data accurately reflect the source documents and the patient's participation.The GCDMP (Chapter: CRF Design and Data Collection) reinforces this by stating that while data managers ensure design quality and CRAs verify consistency with source data, the investigator is legally responsible for CRF accuracy.Thus, option D (Investigator) is correct, as it aligns with both GCP and CCDM standards.
(CCDM-Verified Sources)ICH E6(R2) GCP, Section 4.9 Records and Reports (Investigator Responsibilities) SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 5.1 Investigator's Role in Data AccuracyFDA 21 CFR Part 312.62 Investigator Recordkeeping and Record Retention
Post your Comments and Discuss SCDM CCDM exam prep with other Community members:
Our website is free, but we have to fight against AI bots and content theft. We're sorry for the inconvenience caused by these security measures. You can access the rest of the CCDM content, but please register or login to continue.